Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testingLisa R. Susswein, Wendy K. Chung, Zhixiong Xu et al.|Genetics in Medicine|2015Cited by 292
Germline pathogenic variants identified in women with ovarian tumorsNatalie J. Carter, Kathleen S. Hruska, Megan L. Marshall et al.|Gynecologic Oncology|2018Cited by 59
Differences in cancer prevalence among CHEK2 carriers identified via multi-gene panel testingErin G. Sutcliffe, Kathleen S. Hruska, Amy Stettner et al.|Cancer Genetics|2020Cited by 39
Apparently Heterozygous TP53 Pathogenic Variants May Be Blood Limited in Patients Undergoing Hereditary Cancer Panel TestingJessica L. Mester, Kathleen S. Hruska, Sarah A. Jackson et al.|Journal of Molecular Diagnostics|2019Cited by 23
Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer DiagnosisKristin A. Theobald, Benjamin D. Solomon, Lisa R. Susswein et al.|Annals of Surgical Oncology|2018Cited by 10